Skip to main content
SpringerLink
Log in

Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy?

  • Current Opinion
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Lipodystrophy complications, including lipoatrophy (pathological fat loss) and metabolic complications, have emerged as important long-term toxicities associated with antiretroviral therapy in the current era. The wealth of data that has accumulated over the past 6 years has now clarified the contribution of specific antiretroviral drugs to the risk of these clinical endpoints, with evidence that lipoatrophy is strongly associated with the choice of nucleoside reverse transcriptase inhibitor therapy (specifically, stavudine and to a lesser extent zidovudine). The aetiological basis of metabolic complications of antiretroviral therapy has proven to be complex, in that the risk appears to be modulated by a number of lifestyle factors that have made the metabolic syndrome highly prevalent in the general population, with additional contributions from HIV disease status itself, as well as from individual drugs within the HIV protease inhibitor class. The currently licensed non-nucleoside reverse transcriptase inhibitor (NNRTI) drugs, efavirenz and nevirapine, have been proven to have a favourable safety profile in terms of lipodystrophy complications. However, it must be noted that NNRTI drugs also have individual toxicity profiles that must be accounted for when considering and/or monitoring their use in the treatment of HIV infection.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353: 2093–9

    Article  PubMed  CAS  Google Scholar 

  2. Palella Jr F, Cole SR, Chmiel J, et al. Anthropometrics and examiner-reported body habitus abnormalities in the multicenter AIDS cohort study. Clin Infect Dis 2004; 38: 903–7

    Article  PubMed  Google Scholar 

  3. John M, Nolan D, Mallal S. Antiretroviral therapy and the lipodystrophy syndrome. Antivir Ther 2001; 6: 9–20

    PubMed  CAS  Google Scholar 

  4. Chene G, Angelini E, Cotte L, et al. Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients. Clin Infect Dis 2002; 34: 649–57

    Article  PubMed  CAS  Google Scholar 

  5. Amin J, Moore A, Carr A, et al. Combined analysis of two-year follow-up from two open-label randomized trials comparing efficacy of three nucleoside reverse transcriptase inhibitor backbones for previously untreated HIV-1 infection: Ozcombo 1 and 2. HIV Clin Trials 2003; 4: 252–61

    Article  PubMed  CAS  Google Scholar 

  6. Joly V, Flandre P, Meiffredy V, et al. Increased risk of lipoatrophy under stavudine in HIV-1-infected patients: results of a substudy from a comparative trial. AIDS 2002; 16: 2447–54

    Article  PubMed  CAS  Google Scholar 

  7. Gallant J, Staszewski S, Pozniak A, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292: 191–201

    Article  PubMed  CAS  Google Scholar 

  8. Podzamczer D, Ferrer E, Sanchez P, et al. Toxicity and efficacy of 3TC/EFV associated with stavudine or abacavir in antiretroviral-naive patients: 48-week results of a randomized open and multicenter trial (ABCDE Study) [abstract 716]. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)

  9. Powderly W, Cahn P, Raffi P, et al. Lipid abnormalities and body habitus in a double-blind, randomized, controlled trial comparing emtricitabine to stavudine in HIV+ ART-naive patients [abstract 717]. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)

  10. Murphy R, Katlama C, Weverling G-J, et al. Fat redistribution and metabolic study (FRAMS) in patients receiving a nucleoside reverse transcriptase inhibitor, or protease inhibitor-based regimen over 4 years: FRAMS II substudy of the Atlantic Study [abstract no. 718]. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)

  11. Carr A, Workman C, Smith D, et al. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial. JAMA 2002; 288: 207–15

    Article  PubMed  CAS  Google Scholar 

  12. Mccomsey G, Ward D, Hessenthaler S, et al. Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 2004; 38: 263–70

    Article  PubMed  CAS  Google Scholar 

  13. Dreschler H, Powderly W. Switching effective antiretroviral therapy: a review. Clin Infect Dis 2002; 35: 1219–30

    Article  Google Scholar 

  14. Bonora E, Kiechl S, Willeit J, et al. Metabolic syndrome: epidemiology and more extensive phenotypic description: cross-sectional data from the Bruneck Study. Int J Obes Relat Metab Disord 2003; 27: 1283–9

    Article  PubMed  CAS  Google Scholar 

  15. Ford E, Giles W, Dietz W. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002; 287: 356–9

    Article  PubMed  Google Scholar 

  16. Ford E, Giles W, Mokdad A. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444–9

    Article  PubMed  Google Scholar 

  17. Zhu S, St-Onge M, Heshka S, et al. Lifestyle behaviors associated with lower risk of having the metabolic syndrome. Metabolism 2004; 53: 1503–11

    Article  PubMed  CAS  Google Scholar 

  18. Carnethon M, Loria C, Hill J, et al. Risk factors for the metabolic syndrome: the coronary artery risk development in young adults (CARDIA) study, 1985-2001. Diabetes Care 2004; 27: 2707–15

    Article  PubMed  Google Scholar 

  19. Laaksonen D, Niskanen L, Lakka H, et al. Epidemiology and treatment of the metabolic syndrome. Ann Med 2004; 36: 332–46

    Article  PubMed  CAS  Google Scholar 

  20. Bonora E, Kiechl S, Willeit J, et al. Carotid atherosclerosis and coronary heart disease in the metabolic syndrome: prospective data from the Bruneck study. Diabetes Care 2003; 26: 1251–7

    Article  PubMed  Google Scholar 

  21. Ford E. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. Atherosclerosis 2004; 173: 309–14

    Article  PubMed  CAS  Google Scholar 

  22. Solymoss B, Bourassa M, Campeau L, et al. Effect of increasing metabolic syndrome score on atherosclerotic risk profile and coronary artery disease angiographic severity. Am J Cardiol 2004; 93: 159–64

    Article  PubMed  Google Scholar 

  23. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003 Jun 11; 289(22): 2978–82

    Article  PubMed  CAS  Google Scholar 

  24. Grunfeld C, Pang M, Doerrler W, et al. Lipids, lipoproteins, triglyceride clearance, and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992; 74: 1045–52

    Article  PubMed  CAS  Google Scholar 

  25. Grunfeld C, Kotler D, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86: 27–31

    Article  PubMed  CAS  Google Scholar 

  26. Shor-Posner G, Basit A, Lu Y, et al. Hypercholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993; 94: 515–9

    Article  PubMed  CAS  Google Scholar 

  27. Drummond F, Mullin C, Poehlman M, and SMART protocol team and the Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA 065). Predictors of low HDL in HIV+ patients: effects of class of antiretroviral therapy and traditional risk factors (CPCRA 065) [abstract no. 712]. Proceedings of the 11th Conference on Retroviruses and Opportunistic Infections; 2004 Feb 8-11; San Francisco (CA)

  28. Van Der Valk M, Kastelein J, Murphy R, et al. Nevirapinecontaining antiretroviral therapy in HIV-1 infected patients results in an anti-atherogenic lipid profile. AIDS 2001; 15: 2407–14

    Article  PubMed  Google Scholar 

  29. Van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral- therapy-naive patients infected with HIV-1. PLoS Med 2004; 1: e19

    Article  PubMed  Google Scholar 

  30. Dieleman J, Jambroes M, Gyssens I, et al. Determinants of recurrent toxicity-driven switches of highly active antiretroviral therapy. The ATHENA cohort. AIDS 2002; 16: 737–45

    Article  Google Scholar 

  31. Klein M, Willemot P, Murphy T, et al. The impact of initial highly active antiretroviral therapy on future treatment sequences in HIV infection. AIDS 2004; 18: 1895–904

    Article  PubMed  CAS  Google Scholar 

  32. Manfredi R, Calza L, Chiodo F. First-line efavirenz versus lopinavir-ritonavir-based highly active antiretroviral therapy for naive patients. AIDS 2004; 18: 2331–3

    Article  PubMed  Google Scholar 

  33. Fumaz C, Munoz-Moreno J, Ferrer M, et al. Efavirenz after two years of treatment: tolerability, quality of life and adherence [abstract no. WePeB5935]. Proceedings of the XV International AIDS Conference; 2004 Jul 11-16; Bangkok, Thailand

  34. Van Leth F, Conway B, Laplume H, et al. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine and/or efavirenz. Antivir Ther 2004; 9: 721–8

    PubMed  Google Scholar 

  35. Van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study. Lancet 2004; 363: 1253–63

    Article  PubMed  Google Scholar 

  36. Stern J, Robinson P, Love J, et al. A comprehensive hepatic safety analysis of nevirapine in different populations of HIV infected patients. J Acquir Immune Defic Syndr 2003; 34Suppl. 1: S21–33

    Article  PubMed  CAS  Google Scholar 

  37. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19: 97–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No funding sources were used to assist in the preparation of the manuscript and no potential conflicts of interest exist that are directly relevant to the contents of the manuscript.

Author information

Authors and Affiliations

  1. Centre for Clinical Immunology and Biomedical Statistics, North Block, Royal Perth Hospital and Murdoch University, 2nd Floor, Wellington Street, Perth, Western Australia, 6000, Australia

    David Nolan

Authors
  1. David Nolan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Nolan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nolan, D. Do Non-Nucleoside Reverse Transcriptase Inhibitors Contribute to Lipodystrophy?. Drug-Safety 28, 1069–1074 (2005). https://doi.org/10.2165/00002018-200528120-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200528120-00002

Keywords

Search

Navigation